Promising new therapies for Behcet's disease

European Journal of Internal Medicine

Volumn 17, Issue 3, 2006, Pages 163-169

  Houman, M H ^a   Hamzaoui, K ^b  

^a LA RABTA HOSPITAL   (Tunisia)

^b UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Behcet's disease; Interferon alpha; Oral tolerization; Treatment; Tumor necrosis factor alpha inhibitors

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; MELPHALAN; MYELOABLATIVE AGENT; PEPTIDE; PEPTIDE 336 351; PREDNISONE; REBAMIPIDE; RETINA S ANTIGEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BEHCET DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTE DEPLETION; MYELOABLATIVE CONDITIONING; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; OPTIC NERVE DISEASE; PAIN ASSESSMENT; RELAPSE; REMISSION; RETINOPATHY; REVIEW; TREATMENT RESPONSE; TUBERCULOSIS; UVEITIS; VISUAL ACUITY;

EID: 33646000598     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2005.11.011     Document Type: Review

References (73)

1. Yurdakul S., Hamuryudan V., and Yazici H. Behçet syndrome. Curr Opin Rheumatol 16 (2004) 38-42
2. Dilsen N. History and development of Behcet's disease. Rev Rhum [Engl Ed] 63 (1996) 512-519
3. Zouboulis C.C. Epidemiology of Adamantiades-Behcet's disease. Ann Med Interne [Paris] 150 (1999) 488-498
4. Direskeneli H. Behcet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60 (2001) 996-1002
5. Hamzaoui K., Ayed K., Slim A., Hamza M., and Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behcet's disease. Clin Exp Immunol 79 (1990) 28-34
6. Ohno S., Ohguchi M., Hirose S., Matsuda H., Wakisaka A., and Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 100 (1982) 1455-1458
7. Ben Ahmed M., Houman H., Abdelhak S., Ben Ghorbel I., Miled M., Dellagi K., et al. MICA transmembrane region polymorphism and HLA B51 in Tunisian Behcet's disease patients. Adv Exp Med Biol 528 (2003) 225-228
8. Ben Ahmed M., Houman H., Miled M., Dellagi K., and Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum 50 (2004) 2291-2295
9. Houman M.H., Hamzaoui A., Smiti-Khanfir M., Ben Ghorbel I., Fki M., and Hamzaoui K. Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun 23 (2004) 267-273
10. Yurdakul S., Mat C., Tuzun Y., Ozyazgan Y., Hamuryudan V., Uysal O., et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44 (2001) 2686-2692
11. Saenz A., Ausejo M., Shea B., Wells G., Welch V., and Tugwell P. Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev (2000) CD001084
12. Meador R., Ehrlich G., and Von Feldt J.M. Behcet's disease: immunopathologic and therapeutic aspects. Curr Rheumatol Rep 4 (2002) 47-54
13. Ando K., Fujino Y., Hijikata K., Izawa Y., and Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol 43 (1999) 312-317
14. Kotake S., Higashi K., Yoshikawa K., Sasamoto Y., Okamoto T., and Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 106 (1999) 586-589
15. Kötter I., Günaydin I., Zierhut M., and Stübiger N. The use of interferon α in Behcet disease: review of the literature. Semin Arthritis Rheum 33 (2004) 320-335
16. Kotter I., Vonthein R., Zierhut M., Eckstein A.K., Ness T., Gunaydin I., et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 33 (2004) 311-319
17. Zouboulis C.C., and Orfanos C.E. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 134 (1998) 1010-1016
18. Hamza M. The long-term treatment with interferon-alfa2a in Behçet's Disease: Seventh International Conference on Behçet's Disease, Pub Adhoua, Tunis, Tunisia; 1997.
19. Kadayifcilar S., Boyacioglu S., Kart H., Gursoy M., and Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 13 (1999) 241-246
20. Budak-Alpdogan T., Demircay Z., Alpdogan O., Direskeneli H., Ergün T., Bayik M., et al. Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms. Ann Hematol 74 (1997) 45-48
21. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 19 (2001) S6-S12
22. Santos Lacomba M., Marcos Martin C., Gallardo Galera J.M., Gomez Vidal M.A., Collantes Estevez E., Ramirez Chamond R., et al. Aqueous humor and serum tumor necrosis factor alphain clinical uveitis. Ophthalmic Res 33 (2001) 251-255
23. Melikoglu M., Fresko I., Mat C., Ozyazgan Y., Gogus F., Yurdakul S., et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 32 (2005) 98-105
24. Falappone P.C., Iannone F., Scioscia C., Grattagliano V., Covelli M., and Lapadula G. The treatment of recurrent uveitis with TNF-alpha inhibitors. Reumatismo 56 (2004) 185-189
25. Estrach C., Mpofu S., and Moots R.J. Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology [Oxford] 41 (2002) 1213-1214
26. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., and Markomichelakis N.N. Effect of infliximab on sight threatening panuveitis in Behcet's disease. Lancet 358 (2001) 295-296
27. Saulsburg F.T., and Mann J.A. Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 49 (2003) 599-600
28. Hassard P.V., Binder S.W., Nelson V., and Vasiliauskas F.A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 120 (2001) 993
29. Rozenbaum M., Rosner I., and Portnoy E. Remission of Behcet's syndrome with TNF alpha blocking treatment. Ann Rheum Dis 61 (2002) 283-284
30. Joesph A., Raj D., Dua H.S., Powell P.T., Lawson P.C., Powell R.J., et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110 (2003) 1449-1453
31. Suhler E., Smith J., Kurz D., Laver A.K., Pickard T.D., and Rosenbaum J.T. A prospective trial of infliximab therapy from patients with refractory uveitis: preliminary results. Arthritis Rheum 48 (2003) S422 [abstract]
32. Gulli S., Arrigo C., Bocchino L., Morgan T.E., Sangari D., Castagna E., et al. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 4 (2003) 19
33. Arayssi T., Hamra R., Awwad S., Kazma I., Homaidan F., Uthman I., et al. Treatment of refractory vitritis in Behçet disease with infliximab. Arthritis Rheum Abstr 46 (2002) S181 [Abstract]
34. Sfikakis P.P. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 suppl 2 (2002) ii51-ii53
35. Melikoglu M., Ozyazgan Y., Fresko I., Mat C., Yurdakul S., Hamuryudan V., et al. The response of treatment resistant uveitis in Behcet's syndrome [BS] to a TNF-a blocker, etanercept: an open study. Arthritis Rheum Abstr 46 (2002) S181
36. Robertson L.P., and Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology [Oxford] 40 (2001) 473-474
37. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31 (2004) 1241-1243
38. Giansanti F., Barbera M.L., Virgili G., Pieri B., Emmi L., and Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur J Ophthalmol 14 (2004) 445-448
39. Sayarlioglu M., Cinal A., Topcu N., and Demirok A. Effect of infliximab on refractory uveitis in Behcet's disease. Ann Pharmacother 38 (2004) 901-902
40. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., Katsilambros N., Theodossiadis P.G., Papaefthimiou S., et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2 140 (2004) 404-406
41. Kram M.T., May L.D., Goodman S., and Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody [infliximab] therapy: report of a case. Dis Colon Rectum 46 (2003) 118-121
42. Haugeberg G., Velken M., and Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 63 (2004) 744-745
43. Andonopoulos A.P., Meimaris N., Daoussis D., Bounas A., and Yiannopoulos G. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behcet's disease. Clin Exp Rheumatol 21 (2003) S57-S58
44. Sarwar H., Mcgrath Jr. H., and Espinoza L.R. Successful treatment of long-standing Neuro-Behçet's disease with infliximab. J Rheumatol 32 (2005) 181-183
45. Behrens F., Zollner T., Moeller B., Kaltwasser J.P., Kaufmann R., and Ochsendorf F.R. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behcet's disease. Adv Exp Med Biol 528 (2003) 561-562
46. Munoz-Fernandez S., Hidalgo V., Fermazdez-Melon J., Schlincker A., and Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet (2001) 358
47. Van Deventer S.J.H. Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 121 (2001) 1242-1245
48. De Kozak Y., Sakai J., Thillaye B., and Faure J.P. S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr. Eye Res 1 (1981) 327-337
49. Gery I., Wiggert B., Redmond T.M., Kuwabara T., Crawford M.A., Vistica B.P., et al. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest Ophthalmol Vis Sci 27 (1986) 1296-1300
50. Nussenblatt R.B., Gery I., and Weiner H.L. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomised masked trial. Am J Ophthalmol 123 (1997) 583-592
51. Thurau S.R., Diedrichs-Möhring M., Fricke H., Burchardi C., and Wildner G. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett 68 (1999) 205-212
52. Stanford M., Whittall T., Bergmeier L.A., Lindblad M., Lundin S., Shinnick T., et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 137 (2004) 201-208
53. Breitbart A., and Ho A.D. Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement. N Engl J Med 344 (2004) 69
54. Rossi G., Moretta A., and Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood 103 (2004) 748-750
55. Lockwood C.M., Hale G., Waldman H., and Jayne D.R. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42 (2003) 1539-1544
56. Matsuda T., Ohno S., Hirohata S., Miyanaga Y., Ujihara H., Inaba G., et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 4 (2003) 19-28
57. Alpsoy E., Er H., Durusoy C., and Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 135 (1999) 529-532
58. Sharquie K.E., Najim R.A., and Abdugharif A.R. Dapsone in Behcet's disease a double-blind, placebo-controlled study. J Dermatol 29 (2002) 267-279
59. Hamuryudan V., Mat C., Saip S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet's syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128 (1998) 443-450
60. Yazici H., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behcet's syndrome. New Engl J Med 322 (1990) 281-285
61. Simsek H., Dündar S., and Telatar H. Treatment of Behcet's disease with indometacin. Int J Dermatol 30 (1991) 54-57
62. Davatchi F., Shahram F., Chams H., et al. Methotrexate for cular lesions of Behcet's disease. Cohort study on 262 patients. Arthritis Rheum 41 356 (1998)
63. Hamuryudan V., Özyazgan Y., Hizli N., et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 40 (1997) 769-774
64. Mudun B.A., Ergen A., Ipcioglu S.U., et al. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm 9 (2001) 219-229
65. Özyazgan Y., Yurdakul S., Yazici H., et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 76 (1992) 241-243
66. Masuda K., Nakajima A., Urayama A., et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1 (1989) 1093-1096
67. Mochizuki M. Immunotherapy for Behcet's disease. Intern Rev Immunol 14 (1997) 49-66
68. Houman M.H., Bchir S., Ben Ghorbel I., Ben Ahmed M., Lamloum M., and Miled M. Les manifestations neurologiques de la maladie de Behçet: étude de 27 cas. Rev Méd Int 23 7 (2002) 592-606
69. Hirohata S., Suda H., and Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 159 (1998) 181-185
70. O'Duffy J.D., Robertson D.M., and Goldstein N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 76 (1984) 75-84
71. Houman M.H., Lamloum M., Ben Ghorbel I., Khiari Ben Salah I., and Miled M. Vena cava thrombosis in Behçet's disease. Analysis of a series of 10 cases. Ann Med Interne 150 (1999) 587-590
72. Houman M.H., Lamloum M., Ben Ghorbel I., Khiari Ben Salah I., Lamloum M., and Miled M. Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol 19 Suppl. 24 (2001) S48-S50
73. Erkan F., Kiyan E., and Tunaci A. Pulmonary complications of Behçet's disease. Clin Chest Med 23 (2002) 493-503